FY2026 EPS Estimates for Astrazeneca Cut by Erste Group Bank

Astrazeneca Plc (NYSE:AZN) – Equities researchers at Erste Group Bank cut their FY2026 earnings per share estimates for shares of Astrazeneca in a report issued on Thursday, August 27th. Erste Group Bank analyst H. Engel now expects that the company will earn $10.14 per share for the year, down from their prior estimate of $10.25. The consensus estimate for Astrazeneca’s current full-year earnings is $10.19 per share.

A number of other brokerages have also weighed in on AZN. Barclays restated a “buy” rating on shares of Astrazeneca in a research note on Monday, June 1st. HSBC cut shares of Astrazeneca from a “buy” rating to a “hold” rating in a research report on Monday, July 13th. Bank of America restated a “buy” rating on shares of Astrazeneca in a report on Wednesday, July 1st. Deutsche Bank Aktiengesellschaft restated a “sell” rating on shares of Astrazeneca in a research report on Tuesday, June 30th. Finally, JPMorgan Chase & Co. reiterated a “buy” rating on shares of Astrazeneca in a research report on Tuesday, June 30th. Thirteen analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $206.67.

Astrazeneca Stock Performance

NYSE AZN opened at $162.43 on Monday. The stock has a market capitalization of $251.91 billion, a PE ratio of 24.28, a P/E/G ratio of 1.27 and a beta of 0.25. Astrazeneca has a 1 year low of $145.79 and a 1 year high of $212.71. The company’s 50 day simple moving average is $170.58 and its two-hundred day simple moving average is $184.42. The company has a debt-to-equity ratio of 0.47, a current ratio of 0.89 and a quick ratio of 0.67.

Astrazeneca (NYSE:AZN) last posted its earnings results on Monday, July 27th. The company reported $2.63 earnings per share for the quarter, beating analysts’ consensus estimates of $2.50 by $0.13. Astrazeneca had a return on equity of 31.45% and a net margin of 17.02%.The business had revenue of $15.38 billion during the quarter, compared to analyst estimates of $15.44 billion. During the same quarter in the previous year, the firm earned $2.17 EPS. The company’s quarterly revenue was up 6.4% compared to the same quarter last year.

Institutional Investors Weigh In On Astrazeneca

Several institutional investors and hedge funds have recently bought and sold shares of AZN. Amundi raised its holdings in shares of Astrazeneca by 6.7% during the second quarter. Amundi now owns 16,422,784 shares of the company’s stock valued at $3,114,088,000 after acquiring an additional 1,036,635 shares in the last quarter. Tanager Wealth Management LLP lifted its stake in Astrazeneca by 15.3% in the second quarter. Tanager Wealth Management LLP now owns 1,550 shares of the company’s stock worth $290,000 after acquiring an additional 206 shares during the period. Ameritas Advisory Services LLC bought a new stake in Astrazeneca in the second quarter valued at $1,152,000. Kintra Wealth LLC boosted its holdings in Astrazeneca by 32.9% in the second quarter. Kintra Wealth LLC now owns 3,468 shares of the company’s stock valued at $658,000 after acquiring an additional 858 shares in the last quarter. Finally, Endeavor Private Wealth Inc. purchased a new position in Astrazeneca during the 2nd quarter valued at $292,000. Hedge funds and other institutional investors own 20.35% of the company’s stock.

Astrazeneca Company Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.